论文部分内容阅读
树突状细胞(dendritic cell,DC)是抗原呈递功能最强、唯一能在体内激活初始型T细胞的抗原呈递细胞(antigen presentingcells,APC),同时可以通过主要组织相容性复合体Ⅱ类分子(major histocompatibility complex classⅡmolecules,MHCⅡ)和MHCⅠ类分子途径呈递抗原,并提供充分的共刺激信号,在T细胞抗肿瘤免疫应答的启动、调控过程中起着关键的作用。用基因工程技术将肿瘤抗原基因和一些特殊的细胞因子基因导入DC,可提高DC的抗原提呈功能,并提供多个可供识别的抗原表位,克服人类白细胞抗原(human leukocyte antigen,HLA)限制性,在对肿瘤的免疫治疗中日益受到重视。
Dendritic cells (DCs) are the most antigen presenting functionally active antigen presenting cells (APCs) that can activate naive T cells in vivo. They can also pass through the major histocompatibility complex class II molecules (MHCⅡ) and MHC class Ⅰ (MHCⅡ) pathways and provide sufficient co-stimulatory signals, which plays a key role in the initiation and regulation of T cell anti-tumor immune responses. The introduction of tumor antigen genes and some special cytokine genes into DCs through genetic engineering can enhance the antigen presenting function of DCs and provide multiple epitopes for recognition to overcome human leukocyte antigen (HLA) Restrictive, in the immune treatment of tumors is increasingly valued.